Open AccessUse of Recombinant Canine Granulocyte Colony‐Stimulating Factor to Decrease Myelosuppression Associated with the Administration of Mitoxantrone in the Dog
Author(s) -
Ogilvie Gregory K.,
Obradovich Joyce E.,
Cooper Mary F.,
Walters Lisa M.,
Salman M.D.,
Boone T.C.
Publication year - 1992
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.1992.tb00985.x
Subject(s) - mitoxantrone , medicine , granulocyte colony stimulating factor , neutropenia , hematopoietic growth factor , haematopoiesis , pharmacology , granulocyte , gastroenterology , chemotherapy , stem cell , biology , genetics
Ten dogs were given mitoxantrone at a dose of 5 mg/m 2 body surface area intravenously. Recombinant canine granulocyte colony‐stimulating factor (rcG‐CSF) was administered subcutaneously daily for 20 days after an infusion of mitoxantrone in five of these dogs to determine the effect of the hematopoietic growth factor on the duration and severity of myelosuppression. The median neutrophil counts dropped below normal (<3,000/uL) for 2 days in the dogs that received rcG‐CSF, and for 5 days in the dogs that received only mitoxantrone. Four of five dogs not treated with rcG‐CSF and none of those receiving rcG‐CSF developed serious neutropenia (